Nurix Therapeutics shares are trading higher after Truist Securities initiated coverage on the stock with a Buy rating and announced a price target of $36.
Portfolio Pulse from Benzinga Newsdesk
Nurix Therapeutics shares are trading higher after Truist Securities initiated coverage on the stock with a Buy rating and announced a price target of $36.
July 31, 2024 | 6:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nurix Therapeutics shares are trading higher following Truist Securities' initiation of coverage with a Buy rating and a $36 price target.
The initiation of coverage with a Buy rating and a specific price target of $36 by Truist Securities is a strong positive signal for investors, likely driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100